PAMP
HUMA icon

Polar Asset Management Partners’s Humacyte HUMA Stock Holding History

Polar Asset Management Partners’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$41K Buy
+52,600
New +$48.7K ﹤0.01% 755

Other funds holding HUMA

AP
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Polar Asset Management Partners's HUMA Position: Q2 2025 in Review

Polar Asset Management Partners sold out of Humacyte (HUMA) in Q2 2025, closing a stake of 500,000 shares — an estimated $853K sold.

Polar Asset Management Partners first reported a position in HUMA in Q1 2025 and held it in 1 quarter. The position peaked at $853K in Q1 2025. 156 funds tracked by Wall St. Rank hold HUMA as of Q2 2025.

  • Polar Asset Management Partners reported no remaining Humacyte position as of Q2 2025 after selling out during the quarter.
  • Polar Asset Management Partners sold 500,000 Humacyte shares in Q2 2025, an estimated $853K.
  • Polar Asset Management Partners first reported a position in Humacyte in Q1 2025 and held it in 1 quarter.
  • Polar Asset Management Partners's Humacyte position peaked at $853K in Q1 2025.
  • 156 funds tracked by Wall St. Rank held Humacyte as of Q2 2025.

Based on Polar Asset Management Partners's 13F filing for Q2 2025, filed 14 Aug 2025.